Biomarin Pharmaceutical Inc. (BMRN) Market Performance
- Closing price (Thursday, 22 Oct 2026, 05:59 AM Central Europe): USD 55.21
- Price change during the 24‑hour period: +3.24 %
- Shares outstanding: 193.5 million
- Market capitalization: USD 10.6 billion
- Trading volume in the last 24 hours: USD 196.1 million
- Performance since last month‑end: –11.9 %
- Simple moving average (200 days): USD 58.52
- 52‑week high: USD 70.98 (08/12/2026)
- 52‑week low: USD 49.26 (05/18/2026)
Related Stock Movements (24‑hour period)
| Symbol | Company | % Change | Current Price | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|---|
| SEIC | Sei Investments | +2.25 % | 108.43 | 12.6 | 18.5 |
| BWXT | Bwx | –1.17 % | 135.11 | 12.5 | 35.35 |
| STRL | Sterling Infrastructure | –2.65 % | 412.96 | 12.6 | 29.17 |
| PINS | +2.86 % | 22.95 | 12.7 | 171.16 | |
| SMMT | Summit Therapeutics | +3.34 % | 15.83 | 12.5 | – |
Company Overview
Biomarin Pharmaceutical Inc. is a biotechnology firm headquartered in San Rafael, United States. The company focuses on the development and commercialization of therapeutic enzyme products. Its portfolio includes products for lysosomal storage diseases and serious burn treatments, as well as analytical and diagnostic solutions in carbohydrate biology through its subsidiaries. Biomarin is listed on the Nasdaq stock exchange. The company went public with an initial public offering on 23 July 1999. Further details can be found on the company’s website at www.biomarin.com .
